131I-tositumomab radioimmunotherapy: initial tumor dose-response results using 3-dimensional dosimetry including radiobiologic modeling.

Dewaraja, Yuni K; Schipper, Matthew J; Roberson, Peter L; Wilderman, Scott J; Amro, Hanan; Regan, Denise D; Koral, Kenneth F; Kaminski, Mark S; Avram, Anca M

Dewaraja, Yuni K; Schipper, Matthew J; Roberson, Peter L; Wilderman, Scott J; Amro, Hanan; Regan, Denise D; Koral, Kenneth F; Kaminski, Mark S; Avram, Anca M.

Affiliation

Dewaraja YK; Department of Radiology, University of Michigan, Ann Arbor, Michigan 48109, USA. yuni@umich.edu

J Nucl Med ; 51(7): 1155-62, 2010 Jul.

Article in En | MEDLINE | ID: mdl-20554734

Subject(s)

Algorithms; Antibodies, Monoclonal/therapeutic use; Antineoplastic Agents/therapeutic use; Neoplasms/radiotherapy; Radioimmunotherapy/methods; Radiometry/methods; Radiopharmaceuticals/therapeutic use; Cell Proliferation/drug effects; Dose-Response Relationship, Radiation; Humans; Models, Biological; Monte Carlo Method; Radiometry/statistics & numerical data; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Radiometry / Algorithms / Radioimmunotherapy / Radiopharmaceuticals / Antibodies, Monoclonal / Neoplasms / Antineoplastic Agents Type of study: Health_economic_evaluation / Prognostic_studies Limits: Humans Language: En Year: 2010 Type: Article

Fulltext

XML

PubMed Links

Search on Google